An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment

Meletios A. Dimopoulos, Joseph Mikhael, Evangelos Terpos, Xavier Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith Stockerl-Goldstein, Paul G. Richardson

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Renal impairment (RI) is a relatively common complication of multiple myeloma, which increases in frequency as disease becomes more advanced and recovery of renal function becomes less likely as patients progress through lines of therapy. Clinical trials in the relapsed/refractory multiple myeloma (RRMM) setting have not uniformly included patients with RI or robustly reported their outcomes. Here, we review existing data among patients with RI and RRMM across drug classes (including immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T-cell therapies, and exportin-1 inhibitor) to provide an improved understanding of available treatment options for this important population. We highlight data from pivotal clinical trials, including data relating to renal response (as defined by the International Myeloma Working Group) and discuss real-world experiences in patients with RI, where applicable. Despite substantial advances in RRMM treatment, the presence of RI remains associated with reduced overall survival. Consistent inclusion of patients with RI, and uniform reporting of their outcomes, should be encouraged in future prospective trials of treatments for RRMM.

Original languageEnglish
JournalTherapeutic Advances in Hematology
StatePublished - Apr 2022


  • multiple myeloma
  • refractory
  • relapsed
  • renal impairment
  • renal response


Dive into the research topics of 'An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment'. Together they form a unique fingerprint.

Cite this